Safety Study of Intravenous MiraMSC in Older Adults With Mild to Moderate Frailty Syndrome

The purpose of this Phase I, open-label study is to evaluate the safety and tolerability of intravenous MiraMSC-FS-001 in older adults with mild to moderate frailty syndrome. MiraMSC-FS-001 is an investigational product consisting of allogeneic umbilical cord-derived mesenchymal stem cells (UCMSCs). Eligible participants will receive intravenous administration of MiraMSC-FS-001.

NCT Number	NCT07705464
Lead Sponsor	Miracle Biomedical Co., Ltd.
Conditions	Frailty
Enrollment	12 participants
Start Date	2026-12-01
Primary Completion	2028-06-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-15